This publication is entirely developed by the EHC to inform its National Member Organisations about the rapidly changing landscape of health policy and legislative developments which have a direct impact on the bleeding disorders community.

On 3-4 February, in Italy, the EHC and Kedrion organised a workshop on Factor X (FX) deficiency, bringing together patient representatives and healthcare providers.

The EHC released the first 2025 issue of its Novel Treatment Review (NTR), a periodic review of novel treatments in rare bleeding disorders.

The European Haemophilia Consortium (EHC) successfully held its 2025 Strategic Retreat on January 18–19 in Brussels. This key event brought together the EHC Steering Committee, Medical Advisory Group and thematic committee representatives, and staff.

As we reflect on the past year, the EHC is deeply grateful for the dedication of our NMOs, partners, and community. Let’s move forward with renewed energy!

The EHC welcomed the opportunity to contribute to the European Commission’s public consultation on the draft implementing regulation on Joint Scientific Consultations (JSC) for Medicinal Products, for which we issued nine recommendations.